1. Griffith DE, Daley CL. Treatment of Mycobacterium abscessus pulmonary disease. Chest 2022;161:64-75.
5. Weng YW, Huang CK, Sy CL, Wu KS, Tsai HC, Lee SS. Treatment for Mycobacterium abscessus complex-lung disease. J Formos Med Assoc 2020;119 Suppl 1:S58-S66.
8. Jhun BW, Koh WJ. Treatment of Mycobacterium abscessus pulmonary disease. Korean J Med 2019;94:343-352.
10. Tortoli E, Kohl TA, Brown-Elliott BA, et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol 2016;66:4471-4479.
11. Tortoli E, Kohl TA, Brown-Elliott BA, et al. Mycobacterium abscessus, a taxonomic puzzle. Int J Syst Evol Microbiol 2018;68:467-469.
12. Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuberc Lung Dis 2014;18:1141-1148.
13. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.
16. Choi H, Jhun BW, Kim SY, et al. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease. Diagn Microbiol Infect Dis 2018;90:293-295.
17. Lyu J, Kim BJ, Kim BJ, et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med 2014;108:1706-1712.
18. Park J, Yoon SH, Kim JY, Gu KM, Kwak N, Yim JJ. Radiographic severity and treatment outcome of Mycobacterium abscessus complex pulmonary disease. Respir Med 2021;187:106549.
19. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J, Nienhaus A. Microbiological and clinical outcomes of treating non-
Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and metaanalysis. Chest 2017;152:120-142.
20. Kang N, Jeon K, Kim H, et al. Outcomes of inhaled amikacincontaining multidrug regimens for Mycobacterium abscessus pulmonary disease. Chest 2021;160:436-445.
22. Kwak N, Dalcolmo MP, Daley CL, et al. M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J 2019;54:1801991.
23. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012;186:917-925.
25. Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902.
26. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 2017;72:ii1-ii64.
27. Park YE, Park SY, Jhun BW, et al. Treatment outcome of continuation of intravenous amikacin for Mycobacterium abscessus pulmonary disease with a persistent culture positivity after the treatment initiation. J Infect Chemother 2022;28:1098-1104.
31. Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim JJ. Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome. Chest 2021;159:517-523.
36. Asakura T, Hayakawa N, Hasegawa N, et al. Long-term outcome of pulmonary resection for nontuberculous mycobacterial pulmonary disease. Clin Infect Dis 2017;65:244-251.
37. Kim JY, Lee HW, Yim JJ, Kwak N. Outcomes of adjunctive surgery in patients with nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest 2023;163:763-777.